229 related articles for article (PubMed ID: 25450320)
1. Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.
Kuragano T; Yahiro M; Kida A; Furuta M; Nagasawa Y; Hasuike Y; Nanami M; Nakanishi T
Int J Artif Organs; 2014 Dec; 37(12):865-74. PubMed ID: 25450320
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.
Wan L; Zhang D
Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of model predictive control for improved anemia management.
Brier ME; Gaweda AE; Dailey A; Aronoff GR; Jacobs AA
Clin J Am Soc Nephrol; 2010 May; 5(5):814-20. PubMed ID: 20185598
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
6. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
Kuragano T; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Kitamura K; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura I; Nakanishi T
Kidney Int; 2014 Oct; 86(4):845-54. PubMed ID: 24759150
[TBL] [Abstract][Full Text] [Related]
7. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
9. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
Webb L; Gilg J; Wilkie M
Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
Sany D; Elsawy AE; Elshahawy Y
Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
[TBL] [Abstract][Full Text] [Related]
11. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
[TBL] [Abstract][Full Text] [Related]
12. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
Kapoian T; O'Mara NB; Singh AK; Moran J; Rizkala AR; Geronemus R; Kopelman RC; Dahl NV; Coyne DW
J Am Soc Nephrol; 2008 Feb; 19(2):372-9. PubMed ID: 18216316
[TBL] [Abstract][Full Text] [Related]
13. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
14. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
15. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
16. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
17. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
Musanovic A; Trnacevic S; Mekic M; Musanovic A
Med Arch; 2013; 67(5):361-4. PubMed ID: 24601173
[TBL] [Abstract][Full Text] [Related]
18. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
19. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and iron for anemia in HIV-infected patients undergoing maintenance hemodialysis in China: a cross-sectional study.
Peng L; He Y; Zhang J; Hong D; Li G
BMC Nephrol; 2022 Feb; 23(1):60. PubMed ID: 35135490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
